In a very recent study on FHA and controls, Makollé et al. demonstrated that the serum levels of anti-Mullerian hormone (AMH) were significantly lower in FHA patients without polycystic ovarian morphology (PCOM) than in controls [4]. The gene discussed is AMH; the disease is hypoalphalipoproteinemia, primary, 1.